Content about Perrigo

June 17, 2013
Perrigo to acquire Fera's ophthalmic portfolio for up to $129 million

Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said.

ALLEGAN, Mich. — Perrigo Co. will pay up to $129 million to buy Fera Pharmaceuticals' portfolio of ophthalmic products, Perrigo said Monday.

Perrigo said the acquisition from Locust Valley, N.Y.-based Fera included an upfront payment of $93 million and milestone payments of about $36 million. The products include generic ophthalmic sterile ointments and solutions and generated sales of more than $30 million in 2012.

May 29, 2013
FDA approves Perrigo overactive bladder drug

The Food and Drug Administration has approved a generic drug for incontinence made by Perrigo Co., the drug maker said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a generic drug for incontinence made by Perrigo Co., the drug maker said Wednesday.

Perrigo announced the approval of trospium chloride extended-release capsules in the 60 mg strength, a once-daily treatment for overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. The drug is a generic version of Allergan's Sanctura XR, which has annual sales of $54 million, according to Symphony Health Solutions.

May 13, 2013
Got private label? Perrigo unveils store-brand OTC image campaign

Perrigo on Monday announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter store-brand medications.

ALLEGAN, Mich. — Perrigo on Monday announced it has kicked off a broad industry marketing and communications campaign to raise awareness for, and consumer confidence in, generic over-the-counter store-brand medications. 

May 8, 2013
Perrigo: $10 billion in Rx sales may switch OTC through 2018

There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday.

ALLEGAN, Mich. — There is as much as $10 billion in branded pharmaceutical sales that could make the switch from prescription-only to over-the counter in the next five years, suggested Joseph Papa, Perrigo chairman, CEO and president, to analysts on Tuesday. And as much as $5 billion in the next three years. 

April 1, 2013
Perrigo closes Velcera acquisition

Perrigo Co. has completed its acquisition of a Pennsylvania-based animal health company, the drug maker said.

ALLEGAN, Mich. — Perrigo Co. has completed its acquisition of a Pennsylvania-based animal health company, the drug maker said Monday.

Perrigo announced that it has closed its purchase of Yardley, Pa.-based Velcera for about $160 million. The company makes OTC products for pets, specializing in products traditionally dispensed only by veterinarians. Its products include PetArmor, a flea and tick repellent that had sales of more than $100 million last year.

March 18, 2013
Perrigo launches store-brand guaifenesin 600-mg extended-release tablets

Perrigo announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets.

ALLEGAN, Mich. — Perrigo on Monday announced that it has begun shipments of guaifenesin 600-mg extended-release tablets. It's the first product that is generically equivalent to Reckitt Benckiser's Mucinex 600-mg extended-release tablets. 

February 21, 2013
GPhA appoints board of directors for 2013

The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.

ORLANDO, Fla. — The Generic Pharmaceutical Association re-elected its chairman from last year and appointed a new board of directors for 2013 whose members run from A to Z — as in Amneal to Zydus.

"We are grateful for the vision and support of the 2012 board of directors, and we are excited to move ahead with our chairman and our 2013 board," GPhA president and CEO Ralph Neas said. "In a time of enormous change and growth for our industry, leadership is critical."

February 5, 2013
FDA approves Perrigo testosterone gel

The Food and Drug Administration has approved a testosterone gel product made by Perrigo, the drug maker said.

ALLEGAN, Mich. — The Food and Drug Administration has approved a testosterone gel product made by Perrigo, the drug maker said Tuesday.

Perrigo announced the approval of the testosterone gel in the 1% strength for the treatment of men with low or no testosterone.

The drug is bioequivalent to AbbVie's AndroGel, which has annual sales of about $705 million, according to Symphony Health.

February 4, 2013
Perrigo launches generic scalp medicine

Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.

ALLEGAN, Mich. — Drug maker Perrigo has launched a generic drug for treating problems of the scalp, the company said.

Perrigo announced the launch of clobetasol emulsion propionate foam in the 0.05% strength, a generic version of GlaxoSmithKline's Olux-E. The drug is used to treat moderate to severe dermatosis of the scalp.

February 4, 2013
Perrigo: Already-strong private label growth will get additional boost from Rx-to-OTC switch

Perrigo chairman, CEO and president Joe Papa shared with analysts that private label OTCs are trending strong and that growth will be sustained going forward with the number of projected Rx-to-OTCs on the horizon.

ALLEGAN, Mich. — Perrigo chairman, CEO and president Joe Papa on Friday shared with analysts that private label OTCs are trending strong and that growth will be sustained going forward with the number of projected Rx-to-OTCs on the horizon. 

February 1, 2013
Perrigo acquires Velcera pet care company

Leading private-label supplier Perrigo has acquired pet health company Velcera for $160 million.

NEW YORK — Leading private-label supplier Perrigo has acquired pet health company Velcera for $160 million.

The deal follows last fall’s acquisition of Sergeants and signals Perrigo’s intent to accelerate growth in areas beyond its traditional businesses of consumer health care, nutrition products and prescriptions. Velcera is a pet health company best known for its PetArmor brand of flea and tick products that are widely available at retailers nationwide, much to the chagrin of veterinarians. PetArmor had sales of $60 million last year.

January 25, 2013
Perrigo introduces new packaging for infant formula

Perrigo Nutritionals is introducing new packaging that the company said would make providing nutrition to infants more convenient.

GEORGIA, Vt. — Perrigo Nutritionals is introducing new packaging that the company said would make providing nutrition to infants more convenient.

January 24, 2013
Perrigo, Ther-Rx announce availability of Gynazole-1

Perrigo and a subsidiary of K-V Pharmaceutical Co. have launched a new drug for yeast infections in women, the two companies said.

ST. LOUIS — Perrigo and a subsidiary of K-V Pharmaceutical Co. have launched a new drug for yeast infections in women, the two companies said.

Perrigo and Ther-Rx Corp. announced the availability of Gynazole-1 (butoconazole nitrate vaginal cream) in the 2% strength for treating yeast infections in nonpregnant women.

Ther-Rx has a partnership with Perrigo to manufacture the drug.

January 22, 2013
Perrigo launches private label equivalent to Nicorette mini lozenge

Perrigo announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor), comparable to GlaxoSmithKline's Nicorette mini lozenge.

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor), comparable to GlaxoSmithKline's Nicorette mini lozenge. 

"This launch strengthens Perrigo's leading store brand position in smoking cessation products, which also includes coated and uncoated flavored gums and regular size lozenges," stated Joseph Papa, Perrigo's chairman, president and CEO. 

January 15, 2013
Reuters: CVS/pharmacy will stock Tylenol in only half of its stores

CVS/pharmacy has decided to stock Tylenol pain reliever in only half of its stores, according to a Reuters report published Monday.

NEW YORK — CVS/pharmacy has decided to stock Tylenol pain reliever in only half of its stores, according to a Reuters report published Monday. 

According to the report, CVS will stock Tylenol in each market, but not in each store as CVS seeks to plug any out-of-stock holes left behind by the initial recall of Tylenol three years ago and the brand's slow trek back to shelf. 

December 28, 2012
Perrigo acquires remaining stake in Cobrek Pharmaceuticals

Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals.

ALLEGAN, Mich. — Solidifying Perrigo’s leadership position in topical foam-based generic prescription pharmaceuticals, the company announced it has signed a definitive merger agreement and completed the acquisition of Cobrek Pharmaceuticals, a privately-held, Chicago-based drug development company, for approximately $45 million.

November 28, 2012
FDA approves Perrigo, Cobrek scalp psoriasis treatment

The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

ALLEGAN, Mich. — The Food and Drug Administration has approved a drug from Perrigo and Cobrek Pharmaceuticals for treating scalp conditions.

Perrigo said that Cobrek, with which it is partnering, had received approval for betamethasone validate foam in the 0.12% strength. The drug is a generic version of Luxiq foam, made by GlaxoSmithKline subsidiary Stiefel Labs, and is used to treat corticosteroid-responsive skin conditions of the scalp, also known as scalp psoriasis.

The branded version of the drug has annual sales of about $40 million, according to Perrigo.

November 8, 2012
Perrigo chief: Store brands big driver behind OTC growth, prepping launch of Mucinex equivalent

Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows.

ALLEGAN. Mich. — Business for OTC store brands is expected to boom in the coming year, Perrigo chairman and CEO Joseph Papa told analysts discussing the private-label manufacturer's first-quarter results during a conference call Wednesday, even as the growth rate across the entire OTC category slows. "What we are seeing though, is the continued acceleration of store brand as being the reason why we're seeing the growth in our OTC category. For us to have a 9.4% growth in our OTC category, we think is a strong indication," Papa said. 

October 16, 2012
Perrigo wins tentative approval for generic Zegerid OTC

Perrigo has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application to market over-the-counter omeprazole and sodium bicarbonate capsules in the 20-mg/1,100-mg strength, the store-brand equivalent to Merck's Zegerid OTC.

ALLEGAN, Mich. — Perrigo has received tentative approval from the U.S. Food and Drug Administration for its abbreviated new drug application to market over-the-counter omeprazole and sodium bicarbonate capsules in the 20-mg/1,100-mg strength, the store-brand equivalent to Merck's Zegerid OTC.

Zegerid OTC (omeprazole and sodium bicarbonate capsules 20 mg/1,100 mg), a proton-pump inhibitor indicated to relieve frequent heartburn, had sales of approximately $42 million through food, drug and mass merchandisers for the lastest 12 months.

October 10, 2012
Perrigo launches store-brand nicotine mini lozenges

Perrigo on Wednesday announced that it has received approval from the Food and Drug Administration for its abbreviated new drug applications to market over-the-counter nicotine polacrilex mini lozenge USP in both 2-mg and 4-mg strengths.

ALLEGAN, Mich. — Perrigo on Wednesday announced that it has received approval from the Food and Drug Administration for its abbreviated new drug applications to market over-the-counter nicotine polacrilex mini lozenge USP in both 2-mg and 4-mg strengths. 

The mint-flavored mini lozenge is comparable with GlaxoSmithKline's Nicorette Mini Lozenge and is indicated to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking.

September 18, 2012
NewsBytes — Generics, 9/24/12

Generic drug makers Hospira, Sagent Pharmaceuticals and Teva Pharmaceutical Industries have launched generic versions of a chemotherapy drug made by Sanofi, the three companies said last month.


NEW YORK — Generic drug makers Hospira, Sagent Pharmaceuticals and Teva Pharmaceutical Industries have launched generic versions of a chemotherapy drug made by Sanofi, the three companies said last month.


September 13, 2012
Sergeant's Pet Care gets Perrigo's attention

An expanded offering of private-label pet care products will come soon to retailers' shelves, following the acquisition of Sergeant's Pet Care Products by Perrigo, the leading global provider of store-brand health and personal care items.

ALLEGAN, Mich. — An expanded offering of private-label pet care products will come soon to retailers' shelves, following the acquisition of Sergeant's Pet Care Products by Perrigo, the leading global provider of store-brand health and personal care items.

Perrigo said it signed a definitive agreement to acquire substantially all of the assets of Sergeant's, a privately held Omaha-based company, for $285 million in an all cash deal that enables Perrigo to enter the $8 billion pet care market.

September 7, 2012
Perrigo seeks approval for generic bronchospasm drug

Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.

ALLEGAN, Mich. — Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.

August 28, 2012
Perrigo, Tris Pharma launch generic cough-cold product

Perrigo and Tris Pharma have launched a private-label version of Delsym extended-release oral liquid suspension containing dextromethorphan polistirex.

ALLEGAN, Mich., and MONMOUTH JUNCTION, N.J. — Perrigo and Tris Pharma have launched a private-label version of Delsym extended-release oral liquid suspension containing dextromethorphan polistirex.

The comapnies said the product, which is indicated for the temporary treatment of cough due to minor throat and bronchial irritation, will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

August 8, 2012
FDA approves morphine sulfate oral solution

The Food and Drug Administration has approved an oral painkiller made by Perrigo, the drug maker said Wednesday.

ALLEGAN, Mich. — The Food and Drug Administration has approved an oral painkiller made by Perrigo, the drug maker said Wednesday.

Perrigo announced the approval of morphine sulfate oral solution in the 100-mL/5% strength. The drug is a Schedule II controlled substance and is used to treat moderate to severe acute and chronic pain. Sales of the drug are about $26 million per year, according to Wolters Kluwer Health. Perrigo said it would ship the drug immediately.